Summary:
In immune-competent individuals, human cytomegalovirus (HCMV) infection is associated with impairment of T-cell function. Our goal was to evaluate prospectively whether clinically asymptomatic HCMV infection in allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients, treated pre emptively with ganciclovir, influences T-cell function as well. Mitogen-stimulated T-cell proliferative activity, together with cell surface markers, was tested in 49 patients on days + 30, + 45, + 60, and + 90 after alloHSCT and, additionally, in cases of positive HCMV pp65-antigenemia. HCMV infection was diagnosed in 19 patients. None of them developed HCMV disease. T-cell proliferative activity was significantly decreased on days when HCMV antigenemia was positive as compared to days without antigenemia. The number of pp65-positive cells negatively correlated with proliferative response. Comparison of patients who did experience HCMV infection with those who did not reveals significant decrease of T-cell proliferative activity observed on days + 30 and + 45, a time period when antigenemia was most frequently found to be positive, whereas no difference was detected on days + 60 and + 90. We conclude that, even clinically asymptomatic, HCMV infection has negative impact on T-cell proliferation capacity in alloHSCT recipients. However, pre emptive therapy with ganciclovir makes this immunosuppressive effect transient and restricted to the time of infection duration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gerna G, Baldanti F, Grossi P et al. Diagnosis and monitoring of human infection in transplant recipients. Rev Med Microbiol 2001; 12: 155–175.
Holowiecki J, Kopera M, Gaciong Z et al. Consensus concerning diagnostics, prophylaxis and treatment of HCMV infection in immunocompromised patients. Acta Haematol Pol 1998; 29: 281–290.
Ahn A, Angula A, Chazal P et al. Human cytomegalovirus inhibits antigen presentation by a sequential mutistep process. Proc Natl Acad Sci USA 1996; 93: 10990–10995.
Slobedman B, Mocarski ES, Arvin AM et al. Latent cytomegalovirus down-regulates major histocomatibility complex class II expression on myeloid progenitors. Blood 2002; 100: 2867–2873.
Reyburn HT, Mandelboim O, Vales-Gomez M et al. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997; 386: 514–517.
Kondo K, Kaneshima H, Mocarski ES . Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1994; 91: 11879–11883.
Carney WP, Iacoviello V, Hirsch MS . Functional properties of T lymphocytes and their substets in cytomegalovirus mononucleosis. J Immunol 1983; 134: 390–393.
Kapasi K, Rice GP . Cytomegalovirus infection of peripheral blood mononuclear cells; effects on interleukin-1 and -2 production and responsiveness. J Virol 1988; 62: 3603–3607.
Kotenko SV, Saccani S, Izotova LS et al. Human cytomegalovirus harbors its own unique IL-10 homolog (HCMVIL-10). Proc Natl Acad Sci USA 2000; 97: 1695–1700.
Jones BC, Logsdon NJ, Josephson K et al. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R. Proc Natl Acad Sci USA 2002; 99: 9404–9409.
Spencer JV, Lockridge KM, Barry PA et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002; 76: 1285–1292.
Paulin T, Rindgen O, Lonnquist B . Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 1985; 39: 377–384.
Gerna G, Baldanti F, Lilleri D et al. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplantation receipients. J Clin Microbiol 2000; 38: 1845–1853.
Locatelli F, Percivalle E, Comoli P et al. Human cytomegalovirus (HHCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early treatment of antigenaemia on patients' outcome. Br J Haematol 1994; 88: 64–71.
Salvaneschi L, Perotti C, Zecca M et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41: 1299–1305.
Ljungman P, Griffiths P, Paya C . Definition of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094–1097.
Gerna G, Revello MG, Percivalle E, Morini F . Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232–1237.
Gerna G, Percivalle E, Torsellini M, Revello MG . Standarization of human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polimorphonuclear leukocytes. J Clin Microbiol 1998; 36: 3585–3589.
Moretta A, Maccario R, Fagioli F et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001; 29: 371–379.
Ljungman P, Reusser P, de la Camara R et al. Management of HCMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33: 1075–1081.
Gerna G, Lilleri D, Baldanti F et al. Human cytomegalovirus immediate-early mRNAemia vs pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101: 5053–5060.
Roux E, Helg C, Dumont-Girard F et al. Analysis of T-cell repopulation after bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984–3992.
Montagna D, Locatelli F, Moretta A et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood 2004; 103: 4322–4329.
Sing GK, Garnett HM . The effects of human cytomegalovirus challenge in vitro on subpopulations of T cells from seronegative donors. J Med Virol 1984; 14: 363–371.
Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.
Grow W, Moreb J, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15–19.
Acknowledgements
This work was partly supported by Grants from AIRC (Associazione Italiana Ricerca sul Cancro), CNR (Consiglio Nazionale delle Ricerche), 6th Framework Programme European Community ‘ALLOSTEM’ and IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Policlinico S Matteo, Pavia, to FL.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giebel, S., Maccario, R., Lilleri, D. et al. The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 36, 503–509 (2005). https://doi.org/10.1038/sj.bmt.1705094
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705094